Marilena Vrana Joins ARMONIA 2025 in Athens to Discuss Plasma Access
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Why does the dependency of Europe on the US for plasma for fractionation persist? What does it mean for patient access and health-systems resilience?
These are some of the questions we will explore at ARMONIA’s 1st Conference on Primary Immunodeficiencies on 12 November in Athens, where I will represent PPTA Europe, Plasma Protein Therapeutics Association (PPTA).
Plasma and plasma-derived therapies availability is a public-health issue with very real consequences for people whose lives depend on them. I look forward to a forward-looking, evidence-based discussion with all stakeholders present.
CU in Athens.
12 November 2025
Wyndham Grand Athens
Agenda here.”
Keep up with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy